Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NTRA

+ Watchlist+ Portfolio

Natera, Inc.

Regulated industrySells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$287.47
52-Week Range
$181.00 – $437.41
Market Cap
$41.98B
P/E (TTM)
—
EPS (TTM)
-1.12
Dividend Yield
0.00%
Advanced Metrics
Price/Book
22.35
PEG Ratio
—
Return on Equity
-10.55%
Return on Assets
-6.79%
Gross Margin
65.14%
Operating Margin
-8.54%
Profit Margin
-5.66%
Current Ratio
2.81
Debt/Equity
0.13
Total Debt
$238.84M
Free Cash Flow
$84.54M
Revenue Growth
34.10%
Earnings Growth
—
Enterprise Value
$41.12B

Market Snapshot

About

Natera is a diagnostics and genetic testing company specializing in cell-free DNA (cfDNA) analysis. The company offers non-invasive prenatal testing (NIPT), oncology testing (Signatera for minimal residual disease detection), organ transplant monitoring (Prospera), and carrier screening, using its proprietary Panorama and SNP-based testing platforms for reproductive health and cancer applications.